Cognizant Earnings Call: Bookings Shine Amid Margin Strain

Cognizant Technology Solutions ((CTSH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cognizant’s latest earnings call struck a cautiously upbeat tone, with management emphasizing strong bookings, steady revenue growth and robust EPS gains, even as they acknowledged margin pressure, cash‑flow timing issues and a softer demand backdrop. The message to investors was that strategic initiatives are working, but the transition will not be cost‑free.

Revenue Growth Anchored by North America and Large Deals

Cognizant reported Q1 revenue of $5.4 billion, up 3.9% year over year in constant currency, with North America and the ramp‑up of recently won large deals doing most of the heavy lifting. While growth is hardly explosive, the company is showing resilience versus a mixed IT services backdrop and is leaning on large, longer‑term contracts for stability.

Bookings Surge and Large Deal Engine Accelerates

Bookings were a standout, rising 21% year over year in Q1, as Cognizant signed seven large deals with total contract values above $100 million, including one mega deal over $500 million. Trailing 12‑month bookings climbed 11%, translating into a healthy book‑to‑bill ratio of 1.4 that underpins revenue visibility into the coming quarters.

Margins Edge Higher and EPS Grows Faster Than Sales

Profitability continued to improve, with adjusted operating margin expanding for a fifth straight quarter to 15.6%, up 10 basis points from a year ago despite investment headwinds. Adjusted diluted EPS rose about 14% to $1.40, notably outpacing revenue growth and signaling tighter cost discipline and a more efficient operating model.

AI and Platforms Emerging as Key Growth Drivers

Management underscored accelerating AI momentum, reporting more than 5,000 AI engagements versus roughly 4,000 at year‑end and noting that about 40% of code is now AI‑assisted. New patents for AI Labs and the launch of the Cognizant Innovation Network, aimed at supporting early‑stage AI startups, position the firm to capture higher‑value digital and automation work.

Project LEAP Targets Structural Savings and Higher Margins

Project LEAP is set to reshape Cognizant’s cost base, with expected savings of $200 million to $300 million in 2026 and an even larger impact in 2027. The company lifted its 2026 adjusted operating margin target to 16.0%–16.2%, implying 20 to 40 basis points of annual expansion as the program matures and operational efficiencies scale.

M&A Strategy Strengthens AI and Infrastructure Capabilities

Cognizant continued to deploy capital into targeted acquisitions, highlighting a definitive agreement to buy Atria to bolster AI infrastructure, data center, workplace and network services. Management expects recent deals collectively to add about 150 basis points to revenue growth in 2026, reinforcing the top line while deepening strategic capabilities.

Capital Returns and Balance Sheet Remain Shareholder-Friendly

The company returned roughly $600 million to shareholders in Q1, supported by $1.5 billion in cash and short‑term investments and a net cash position of about $949 million. For the full year, Cognizant plans to return around $1.6 billion, including $1.0 billion of share repurchases, and is guiding to free cash flow conversion of 90%–100% of net income.

Gross Margin Compression Reflects Investment and Bench Build

Despite operating margin progress, Q1 gross margin dipped by about 80 basis points year on year, a reminder that the transformation carries upfront costs. The decline was driven by spending on integrated offerings, higher compensation including salary hikes and lower utilization tied to bench growth as the firm prepares for future demand.

Soft Demand and Discretionary Spend Caution Temper Optimism

Management did not gloss over macro uncertainty, flagging a softening demand environment and increased caution around discretionary projects. This caution is reflected in Q2 guidance and in commentary that smaller, project‑based work is under pressure even as larger, multi‑year deals remain a relative bright spot.

Health Sciences Faces Product-Related Drag

The Health Sciences segment saw its growth clipped by about 300 basis points year over year due to lower revenue from third‑party products linked to the integrated offering strategy. While this is a known drag rather than a structural collapse in client demand, it does limit near‑term segment momentum and underscores the mix‑shift challenges.

Working Capital and Seasonality Weigh on Cash Flow

Cash metrics were softer in the quarter, with days sales outstanding rising to 84 days, up three days both sequentially and versus last year. Q1 free cash flow came in at about $200 million, constrained by a larger bonus payout and normal seasonal patterns, suggesting investors should watch collection trends as the year progresses.

ACV Stagnates as Deals Get Bigger and Longer

Annual contract value was essentially flat, reflecting a portfolio skew toward bigger, longer‑duration contracts and weakness in smaller discretionary work. Management framed this as a trade‑off: steadier, more visible revenue from large deals, but less near‑term uplift from short‑cycle projects that typically boost ACV growth.

Near-Term LEAP Costs to Pressure Cash and Earnings

Project LEAP comes with significant upfront charges in 2026, estimated at $230 million to $320 million, primarily employee severance plus other related costs. While these will be adjusted out of non‑GAAP metrics, they will weigh on cash and reported earnings near term, requiring investors to separate restructuring noise from underlying performance.

Forward Guidance Signals Steady Growth with Upside from Deals

Management guided Q2 constant‑currency revenue growth of 3.2%–4.7% and reaffirmed full‑year growth of 4.0%–6.5%, with acquisitions contributing about 150 basis points and large‑deal ramps plus additional Astra contribution expected to boost the back half. EPS is projected at $5.63–$5.77, implying 7%–9% growth, supported by a modest margin lift to 2026 and continued strong free cash flow and capital returns.

Cognizant’s call painted the picture of a company in disciplined transition: bookings are strong, AI and acquisitions are adding strategic muscle and EPS is growing ahead of revenue, yet margins, cash flow and discretionary demand remain areas to watch. For investors, the story hinges on management’s ability to convert today’s large‑deal and AI momentum into durable, higher‑margin growth without letting near‑term execution risks derail the trajectory.